Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All true, but it remains to be seen whether or not future shares are sold at .03/share. I highly doubt it, especially since they've already sold some at .05/share. Will there be a discount on future investor shares, certainly, that's normal in the process. I would be happy if they sold them at a 30% discount from closing price. So if RGBP was trading at .12-.13/share, having investors buy large chunks at .084 - .091/share or higher would be great. Sell 10M shares at .09/share and you raise $900,000.
That's a much better scenario than going from 50M shares to 120M shares like they did in 2015. Heck sell 20M shares at .09/share and we go from 124M shares to 144M shares OS but with 1.8M in the bank. I think that would do nicely for the company and help the PPS in the long run.
The piecemeal $50,000 investments of friends and family has a much different effect and flavor.
To me it just refers to another friend/personal investor that had to pay up front and they decided to issue shares in 2016 instead of more on 2015 financials. Most likely another undervalued shares sale at .025-.05 that Lander referred to in his open letter stating that this sort of exchange will be ending in this Quarter (maybe this $50,000 is the last which would be a welcome end).
We need the venture capitalists or other big buyers and money coming in at higher than .05/share on the insider deals. Lander has told us that that will end soon. 10-Q shows another $50,000 coming in from friends and family to be filled at most likely .025-.05/share in January. That won't encourage any big money to come in at .12 or higher, but Koos is not concerned like we are because he makes hundreds of thousands/year with 2015 compensation on the 2015 financials at over $1 million to himself.
Quote from "La Mesa Courrier" article:
ENTB's 10Q answers the question of RGBP's $192,000 in revenue in their 10K.
$100,000 was due to Zander agreement and
$92,000 of Research and Development Expenses incurred during the quarter ended November 30, 2015 (ENTB).
Powerball tickets are $2, but chances of winning are less than 1 in 292 million and the jackpot changes each time, so you only have 1 chance and done. For the 1.5B jackpot, to have a 50/50 one time chance, you would have to spend $292 Million dollars in tickets and you would have to spend that each time a new drawing is held, even when the jackpot is only $200 Million or less. It's a guaranteed system that most people lose and that's why those who run it have so much money to put into the drawing.
My chances for a payout with RGBP are much better over time because it's not a one time drawing nor is it even limited to one product pipeline result, but the investment in the ticket can grow over time instead of going into the trash each week. Different perspectives.
A $10,000 investment in powerball tickets will get you 5,000 tickets for one drawing. That will reduce your chances to 5,000/292,000,000 or a chance of success of 1.71 to the negative 5th power (meaning not very good) for a one time drawing. Here, $10,000 would get you over 70,000 shares of RGBP not for one drawing, but for as long as you want to keep them and while a ticket goes to zero in a instant after the drawing if you don't win, shares do not and you can always trade them back in if you feel the value is going down too fast.
There's many ways to view it, but I'll stick with the shares.
Hmmm, let's think about that.
Not much chance of .01 either. Even if RGBP doubled it's current OS from 124M to 250M OS shares by selling shares at .025/share, the company would then have $3.15M in cash and the dilution would only bring PPS value from .13 to .06 on paper. If RGBP had $3M in cash with 1 FDA approved product for trials and another scheduled for Q2 approval with yet another promising pipeline product at NIH/NCATs research, how long do you think it would stay around .06?
No, we are 1 Q away from closing down the pipe of highly discounted shares and the more of those shares are sold in Q1, the more cash on hand at least RGBP should have which in turn gives greater stability to the company as far as completing testing and moving product forward. I don't think we go to the moon in Q1 unless an unforeseen event of positive magnitude occurs regarding NCATS testing for NR2F6 compounds, but sounds like the schedule for that is anticipated to occur later.
In spite of the dilutive shares, I still see good things ahead for 2016 and the company overall is still in a much better situation than Jan 1, 2015, before all the changes started.
1. In 2015 we went from 50M initial shares to 124M OS shares or an increase of 74M shares (30M was to "angel investors"). According to today's letter, the time for more of those undervalued shares is now limited and I think today's letter to start off 2016 was purposeful and meant to create a new tone. So hopefully we don't see more than 30M-40M max of new highly undervalued shares.
2. Q2 IND for NR2F6 - this actually just struck me that this is significant because unlike HemaX and dCellVax, NR2F6 compound testing is now being done by NIH and any formula/compound that they come up with or verify against the 2 compound lists at NCATS has this reality: NR2F6 IND testing will have been performed at GLP lab with compounds already deemed safe for use in humans, i.e. NR2F6 could move quickly forward towards FDA approval and clinical trials without the delays incurred by HemaX and dCellVax!
3. Q2 IND dCellVax response is being prepped by Dr. Santoosh Kesari at John Wayne Cancer Research Center, so that response and experimental data should meet FDA requirements as well. Which means RGBP could have 2 FDA approved products for clinical trials by Q2 and a third IND submitted with possible data from NIH/NCATS for FDA approval. That means last year's Jan 2015 contract with C. Ichim was very realistic in having incentive shares regarding 3 INDs and 3 relationships with outside CROs.
As disappointing as the PPS movement has been, the more I put into perspective what may realistically happen in 2016 and how that will position the company vs. where we were in 2014, it is night and day and as long as Lander follows through with establishing funding and relationships that don't undermine or undervalue the current share price, we should end 2016 much higher than we are now.
We are on much better grounds - it's just going to take time to walk to higher ground. I'm feeling much better about the letter and the chances of success in the future have only increased, not decreased over the past several months.
An Open Letter to Dr. Harry Lander,
Dear Dr. Lander,
The pain of dilution, especially over long periods of time, is like an extreme migraine that won't go away. Do not torture the shareholders by an extracted period of dilution.
If you need to operate, please do so quickly so that the period of recovery can begin quickly. If you must sell shares at a discount, please do so now: sell 40M shares at .05/share and RGBP will have $2,000,000. Surely this is enough to move the research forward while other relationships and non-dilutive funding can be established.
As a shareholder, I would rather endure a 40 million share pop that funds the company for a year that a steady torture of drip, drip .025/share "investments" by insiders and friends over the course of months and years.
Please, raise the funds quickly and announce the end of .025-.05 shares.
Sincerely,
C.V.
A Long Term Shareholder
Anyone else want to sign on?
I really don't think so. Her contract with RGBP is for 3 years and she has until June of 2016 to reach all the milestones for the investment of her bonus shares. If RGBP were to fire or let her go, they would no longer have anyone in house to further in house pipeline research nor the scientist who wrote a lot of the research on NR2F6.
Without giving all the details, if you research where she has studied, with whom and where, she has clearly had a huge impact on establishing the scientific reputation of RGBP, instrumental in bringing on scientific board members and her milestones included establishing 3 INDs along with 3 clinical studies with CROs.... by June 2016.
C. Ichim leaving the company would be a huge blow and not make sense as her life's research is now invested in RGBP.
Well, time to buckle up and sit back for the longer ride and take RGBP off the minute by minute ticker. Overall, a welcome SOTC report that finally gives us some timelines and overview. Most of the data we knew already.
It was a welcome point that Lander was honest in addressing the selling of discounted shares, but we still need to brace for more of those shares (yesterday?) being sold at high discount as Lander said it won't stop until after Q1 2016:
Does anyone know what the $192,000 in revenue is from? Only thing I can recollect is the selling of IP to Zander (sub company of ENTB) for $100,000, which was to be paid in shares, so no cash or real tangible asset for that, but what would the other $92,000 in revenue be from?
I'm fine with straight sale of stock for equity, but when Preferred A shares are sold for .025/share, then what is the company telling investors the value of common shares is?
And if we need to raise several hundred thousand dollars for clinical trials, how many shares need to be sold at .025.
That's the ongoing Koos complaint I have. Until share selling for .025/share stops, our PPS is not going up.
The PR that T. Ichim left RGBP because of health reasons is indeed very questionable. That said, let us remember that T. Ichim helped to cofound Batu before he was hired by RGBP. Why he left Batu for RGBP and then why he left RGBP to return to Batu is problematic, but it may come down to personalities and it may be that Batu's ValloVax is further along than RGBP's dCellVax and T. Ichim was offered a sweeter deal at Batu or a better working relationship.
Also interesting that the Batu PR doesn't even mentioned T. Ichim having been the Chief Scientific Officer at RGBP and the PR contact has the same woman "Dorsee" that RGBP recently hired for it's PRs.
There's definitely a lot of crossover and questions about the relationships these scientists have between the many companies that vie for their names and research. What doesn't change is that yes, T. Ichim did sign over and sell some of his patents and research to RGBP, (it wasn't everything he's ever been involved with, but specific things to RGBP's pipeline). But what RGBP acquired stays with RGBP.
While T. Ichim was Chief Scientific Officer, let's not forget that it has been C. Ichim who has headed up the research and presentations regarding NR2F6 which may be the current focus of the RGBP pipeline development outside of HemaX. And RGBP has contract with Dr. Kesari regarding dCellVax IND research. Now that RGBP has contracted with NIH/NCATS for the compound hits development and fine tuning for NR2F6 and owns a proprietary compound hit process internally, its pipeline development is clearly not dependent on T. Ichim. If we hear news of C. Ichim leaving, then serious red flags arise as from my recollection, she pretty much is all in with RGBP for her research and loses IP if she leaves. T. Ichim loses the IP property that RGBP bought that as I recall was related to dCellVax or DiffronC research.
While his leaving under a questionable PR reason is cause for concern, it is not a death toll. As I stated, Batu, which he helped to found is near clinical trials for ValloVax, T. Ichim may have personally decided that was what he wanted to pursue whole heartedly at this time.
No need to speculate. If people actually read the entire late filing paperwork with SEC, they have to give a reason and the reason was that the independent audit of the fiscal year was delayed. That's the reason.
If you want to speculate as to why the audit was delayed - a) auditor took a long vacation, b) auditor got sick, c) auditor lost paperwork, d) auditor got arrested for fraud in midst of audit, e) auditor couldn't figure out meaning of all the convertible notes filed during year, f) auditor's grandma got sick and he/she had to leave to take care of her, g) [fill in anything you want], you are free to do so as we have no evidence to really support or contradict why.
Likewise
We'll be getting news in the new year. RGBP has notified SEC that they will be late in filing 10K for fiscal year ending 9/30/2015.
Here's looking forward to an organized blitz of good news sometime in January-February that will include HemaX Orphan Drug Status, details on initiation of Phase I trials, dCellVax update, NCATS compound hits...
Form NT 10K
4 My T, I have no crystal ball, but the fact I believe that NCATS can perform 1.5 million tests per day and the fact that RGBP is supplying the NR2F6 cell line and has already IDed certain compounds, the testing can be ramped up pretty quickly. That said, we are going into the holiday season, I have no idea what NCATS load is.... and we don't know how confidential they will be keeping the results, especially if the testing itself is already a part of a broader discussion with a larger entity.
It's a guessing game and I'm not going to try to predict release dates of PRs, but that said, I think the next 1-3 months should have multiple developments on more than one front.
Jan-Mar 2016 should bring us news on the specifics of the start of HemaXellerate human clinical trial enrollment and possible early reactions as the 10 patient study is not blind and updates we were told can be released as they develop (I would hope, given all the time leading up to approval, that the company has been ready to act and implement this trial for some time.
- NCATS initial testing I would think will have been completed to identify or validate RGBP's previous "hit" compounds. After that, how long to verify best dosage, combo compound possibilites etc. is hard to say, but the beauty of the NCATS system is that it can do the work very quickly robotically and shave years and months off the normal timeframe, so it could happen very quickly in best case scenario.
- dCellVax - couple months back RGBP contracted Dr. Santoosh Kesari to specifically test and prove aspects of dCellVax which he is interested in also developing for glioma and not just breast cancer. Company has said there is synergy between studies for NR2F6 and dCellVax, so I think we get update on dCellVax at some point.
These are 3 separate pipeline developments. Furthermore, keep in mind that C. Ichim's contract gave her 18 months to acquire all her incentive shares and she signed a contract that gave her bonus shares for establishment of 3 INDs and 3 contracts for clinical trials as I recall. Those bonus shares expire June 2016. So, in their minds, there was a real possibility of having 3 pipeline products in clinical trials by June 2016.
Love and Light, I actually think there might be a correlation because I came to a similar possible scenario before reading your post. Did anyone else find it curious that the NIH/NCATS agreement mentioned that the robotic testing was to find compounds that impact NR2F6, and this, after an earlier PR from RGBP announced that they had already identified through RGBP's own patented system various compound hits?
My inference is, why contract with NIH to discover something you've already discovered? The possible scenarios are varied, but one is that a larger entity (Pharma company) wants to have validation of the hits with a trusted, national testing laboratory that can do it efficiently and quickly and also go from the initial compound validation to extremely fast testing of various dosages, various compound combinations etc to fine tune the initial discovery. It could be that for NR2F6's potential being so big - remembers it can stop and cure the cancer if successful, not just treat side effects, that a big Pharma is willing to come on board or make a deal if the NIH/NCATS system can validate RGBPs claims.
And then Pfizer or any other big pharma, is only indirectly dealing with Koos and RGBP. It's an optimistic and hopeful scenario - but not beyond reason. Clearly, RGBP is looking to NIH/NCATs capability to validate and fine tune the research they've done on NR2F6 in order to have a narrowed and precise IND with data. And if the testing data is done by the gov's own laboratory, that can go a long way in getting approval as well. It's a great development for RGBP.
First encouraging price action/share trading day since release of positive FDA news. 2015 raised my hopes; now I'm willing to wait for 2016 to bring to fruition those hopes.
Rereading the last PRs and 8Ks there is a lot of good news and significant development.
Some 2015 highlights quick hits:
Hiring of 2 full time scientists in house in the ICHIMs (while Thomas is only a consultant now, Christine is still there and Landers on board as President also has scientific background.
Multiple presentations at national and international scientific meetings (a 1st for BMSN/RGBP)
The acquisition of pertinent T. Ichim's IP and the filing of several new patents expanding the overall IP.
Going from 2 INDs with delays to one approved IND and the other being collaborated on with outside help from well established Dr. in Kesari for dCellVax with opportunity for him to expand dCellVax IND into glioma or file an additional IND.
Concrete developments in the progress of NR2F6 with not only patented process for screening compounds, but now, after inhouse success in identifying candidates, they have JV with national government entity to confirm and refine those or additional compounds for possible cancer cures - THE POTENTIAL here goes far beyond HemaXellerate's.
Outsourcing to capable and known entities what they are not set up to do in house: CRL, NIH/NCATS, Cancer research institutes like the John Wayne Cancer Research Center and others.
Only downside I've had this year is the undervaluing of the company in selling convertible notes at discounts that are way too high and benefit a few insiders much more than any shareholder.
But overall, 2015 has indeed been a huge year of progress for a small company taking bigger steps and the fact that more and more outside scientists and entities are willing to collaborate and work with RGBP is a highly positive sign for the future.
GLTA. Hoping in 2016 I can pay off my mortgage and take my family on a nice vacation with RGBP.
True, we might be leading up to a Feb/Mar run. If it's in proportion to the run in 2013, I'll be more than satisfied.
Great news, no movement, but more chances now for good news in future. Besides HemaX Orphan Drug status and possible news on patient enrollment (when it happens), we have future opportunities for news from NIH/NCATS on compound hits, possible NIH grant funding etc.
Any deal that secures funds without selling the boat I think will go a long way in boosting price.
Enjoy the weekend. Might be wishing too much, but sure would be great to have news from Landers next week on any kind of partnership.
The other thing to keep in mind, prior to recent couple of PRs, Koos always was the lone contact. I don't think he hired someone for 2 PRs that he could have done himself. I think the hiring of Debbie the PR lady with contacts means there might be a lineup of significant developments anticipated over the coming weeks/months to hire someone now. There is hope, but it's not all going to happen in a day.
While the Nov 24 8K upset me for the deals done at .025 and .05/share for minimum return, I went back to reread the filing and interesting to look up the names attached to the "Letter Agreement" attached to the filing: some very interesting people at Cornell and elsewhere.
I guess I have to go back into patience mode, eat my expectations for price results in 2015 and look to 2016 developments to really move the PPS.
2015 certainly has had its scientific accomplishments though, more than any other year and looks like the current setup of research will prove more productive in the future.
Here's another informative NIH/NCATS video: Tissue Chips
And also the fact that their robots can test in a week the equivalent of what one scientist working 8 hours/day 7 days a week would take 12 years to complete!!!
The capability of testing at NCATS is incredible. The video tells us a lot more than the PR actually. Highly recommend watching:Inside the NCATS laboratory
Agreed. Today's unexpected PR gives great hope for future products that we don't have to wait 2 years for as RGBP moves to partnerships with established and respected entities to move its development forward.
NIH/NCATS also is set up to license any prospective compounds to big pharma, so in my view, this is another positive where big pharma can license an RGBP NR2F6 possible compound via NCAT with RGBP benefitting financially. And who knows, if they discover multiple possible compounds, we could get either a bidding war for someone to license them all our they can sell each possible compound to a different Pharmaceutical company and reap the benefits.
We were waiting almost 3 years for HemaX news. Today's news was unexpected - just can't understand lack of volume at all.
Please explain. How can huge money hold back others, private investors, venture capitalists or others from buying up stock?
Check out this video explaining NCATS assay research capabilities:
Inside NCATS laboratory Testing millions of compounds robotically - amazing! NR2F6 will be on the fast track!!!
This news truly is significant and one would expect this to be cruising into .30s and .40s by now.
Watch the video everyone - this partnership with NCATS allows for RAPID development of the drug combinations RGBP is looking for to launch IND for NR2F6, which would be a much bigger development than HemaX. The fact that NCATS and NIH agreed to partnership is significant and wasn't done on the news of FDA approval. Obviously, this has taken time to negotiate and is another solid PR that RGBP's scientists and their research are drawing respect. All the more reason why it's a mystery there isn't a ton of volume today.
As others point out, NIH gives away millions for research, so hopefully we get a PR that shows funding without big dilution so that the bigger hands are confident to come in without being undercut by .05/share deals.
Shorts aren't keeping this down, as there is no volume buying for the shorts to have to manipulate.
WHY isn't there huge volume on news we've been waiting for for so long and today's news even better? That's the question. I gave my theory yesterday, but hoping today's significant PR on a respected partnership moves this up.
GLTA
Anyone care to address when we might get more specific news on location and start of patient enrollment for HemaX. Since the approval process was a long time in coming and RGBP got approval news on Dec 10th, when do most think we should get a PR on specifics and when would trial start?
Kfox, I agree if Harry Lander can accomplish what his job description said was a goal - to team up with a funding partner in a non dilutive way, I think that would be a tremendous boost to company and share price.
Dmort, I bought more shares at .18 and .1999 yesterday and the lack of momentum is sickening here. I know that there are no "new" shares issued, but 5 million "old" and restricted shares are released each month until Feb 2016 from the convertible notes of Feb/Mar 2015.
Remember, RGBP started with 50M shares of which BMSN owned 30M and our divi shares were part of the other 20M for which we were very excited. Well, there are now over 120M issued shares, some still restricted, but many more non restricted and so the float is certainly in the tens of millions and we need several days of million shares trading to move and hold this higher.
Hope it happens - but if not on great news, then when?
You're right, only 83.9M shares in float. Had my last 2 numbers reversed. Sorry. As far a who can be selling, for those of us posting over the last 2 years, we've extensively documented the pattern and history of convertible notes, registered/unregistered shares, incentive shares and the like which can all be found in the 8Ks filed by the company.
2015 has had its great promise and much more advancement in the science and company patents and collaborative efforts of outside entities, which all give hope for the future. The key point now to where price goes in my opinion in directly related to how RGBP raises its funds. I have consistently posted on that. "Angel investors" and Koos himself received convertible notes from Feb-May 2015 for the most part with March loans attached to convertible notes being the heaviest. Those loans where all immediately converted into shares (30 million plus total) that are released at a rate of 1/6th every month beginning on the 6th month from issue (Sept). On December 17th, another 5 million shares will be released.
Here's what TDA has on RGBP shares:
Well, we got our FDA approval, we got positive update for NR2F6 going forward, Koos hired a woman with connections to be a PR name for PR and they sat on FDA approval news for 5 days, one would think, because they had a plan to try to cluster news release for impact. Maybe we get another PR this week or next on some aspect of dCellVax, but with the price reaction and trading pattern, it doesn't look like we are going anywhere fast.
This board isn't going to carry the PPS with millions of shares being released and because Koos is selling shares for .05. Until Koos raises the share price to at least near current trading price and gathers enough funds for a year, outsiders know he has to sell more shares and they are NOT going to buy even at .20 if Koos is going to issue millions of shares around .05 piecemeal to his buddies. We're being sold out because Koos doesn't care.
New president has connections, all these new board members have connections and now that the company has released news publicly, one would expect big money flowing in from those connections on a private level if not an institutional one. The fact we are dropping on the news we've been waiting for is telling unfortunately for me and all those here.
Dmort, what size of float are you counting on. TDAmeritrade info says the float is currently 89.3 million shares, so yesterday's volume did not impact the float at all.
We must remember that 5 million "angel investor" shares are released to the market each month beginning with Sept, so 15M new shares are available for selling and since these shares were given at .028/share, selling them at .18 is, well, very profitable. The $50,000 Koos "loaned" the company and then converted into shares can now be sold at .18 for a value of over $320,000.
Koos again gave away shares on Nov 20 for .025/share. So when the founder and CEO of the company publicly values the company at .025-.05/share less than a month ago, why would outside investors what to pour money into it at .15-.20/share.
The current PPS after FDA approval and other positive developments is a HUGE DISAPPOINTMENT, but for me, the reason goes straight to Koos and how he has handled funding. He and his buddies are making hundreds of thousands off .18/share. They have no need for it to go higher and until we burn through 20M plus shares given away at .03/share, this might not go higher because smart money is leary that Koos values the company at .025-.05/share as recent as November 20, 2015.
Interesting that someone shows up on a board the day a company releases news of FDA approval on their first pipeline drug only to try to tear the company apart, why?
RGBP is a spinoff of BMSN it is true. It is also true that unlike BMSN, RGBP has employees and set out in 2015 setting goals and incentives for the scientists to achieve to bring value to company. 2015, unlike many years with BMSN, has had measurable acheivements and improvements, not the least of which is final FDA approval for a pretty much automatic Orphan Drug status treatment of HemaXellerate. HemaXellerate has advantage not only of orphan drug status and accelerated process, but the Phase I clinical trials only needs 10 patients and no blind testing. Therefore, they don't have to raise millions to engage in a Phase I clinical trial.
2015 has brought patents, outside partners (so I guess Dr. Kesari amongst others, who are working on RGBP's tab at approved national cancer institutes are all part of a scientific scam - NOT.) If RGBP had really followed ENTB and BMSN which were Koos employed only companies for the most part, there would be an argument for WB, but the fact that RGBP is working with outside legitimate companies and scientists with now multiple candidates and 1st FDA approval, it's pretty silly to claim it's all "a scam".
While I don't like Koos' practice of how he prices shares to outside investors and loans to himself - yes this is a problem, you can't bash FDA approval as scam. The only person discredited in doing so is the one claiming such a thing.
AIMO
I thought iHub had rules against posting the same basic message multiple times in a day?
Hey Jack, what happened? Did the boys leave their ammunition in port? Need some cannon fodder.
2015, the Year of Hope for RGBP has come true. Alleluia!
This indeed is a very nice Christmas present.
Thanks LaddyMan. If these weren't registered by "Dynadot", a "Super Privacy Co" and instead were registered by RGBP (you'd think?), I would say it might mean something. Unfortunately, it might just be a private individual looking to make some money as both URLs are up for sale for $2,000 each
http://www.afternic.com/domain/dcellvax.com
New to this board, but it would also help if some of the moderators cleaned up and updated the Company info area above the board. Having old financials and saying "1st PR since 2012" doesn't give a very good impression.
Outside of that, noone should expect a stock to go up 15-30% every day for several days in a row and just hold the high.
I bought small amount a while back when stock was falling at .0105 and was just going to forget about it. But when I noticed the strong steps up, the news and the rocket up this morning and trickle back, I sold at .03 and bought back more shares at .018. Not a major holder here, but the stock was too steep and yes, besides people, there are computers, many computers out there that buy and sell on automatic algorithymns. Not everything is shorts and MM manipulation.
If you're here to buy and hold for long run, you are fine and better off if you don't watch the stock price everyday. Monthly financials will carry the PPS forward if we keep getting good results. Debt pay down with shares has been completed and if the new drug replacement catches on, their number of orders and revenue will jump as well. If you are watching, then most likely you are also anticipating situations of big jumps, where you can sell and accumulate more, something to be expected in penny land.
GLTA